创胜集团-B2023年中期报告
（以存續方式於開曼群島註冊的有限公司）股份代號 :6628 中 期 報 告 2 4 5 10 31 53 54 55 57 58 59 77 •88135 20238 23Kumar Srinivasan20238 23 Walkers Corporate Limited190 Elgin Avenue, George TownGrand Cayman KY1-9008Cayman Islands 218B6-501215123 20238 23Kumar Srinivasan20238 23 3485 20238 23Kumar Srinivasan 8240 Walkers Corporate Limited190 Elgin Avenue, George TownGrand Cayman, KY1-9008Cayman Islands 1617 110 158 6628 http://www.transcenta.com/ •20226 3021.820236 3036.1CDMO•20226 3023.96.320236 3017.620236 30•20226 3010.20.920236309.3•20226 30170.337.620236 30207.9•20226 3058.90.920236 3058.0•20226 30210.135.220236 30245.3CDMO •20226 3021.820236 3036.1CDMO•20226 3023.96.320236 3017.620236 30•20226 30165.838.120236 30203.9•20226 3057.48.720236 3048.7•20226 30204.127.920236 30232.0CDMO 2023 Claudin18.2osemitamab (TST001)IbClaudin18.2(CDE)(MFDS)osemitamab (TST001)IIIosemitamab(TST001)HER2Claudin18.2(G/GEJ)TST003gremlin1(FIH)202332023(AACR) ITST002 (blosozumab) osemitamab (TST001)TST002TST003BMSosemitamab (TST001) 2023 OsemitamabTST001ADCCClaudin18.2 •202312023(ASCO)(GI 2023)osemitamab (TST001)(CAPOX)(G/GEJ)I/II(TranStar102) •20233Claudin18.2PET[89Zr]Zr-DFO-TST001•20233FDAosemitamab (TST001)•20234I/IITranStar102NCT04495296 CosemitamabCAPOXGosemitamabCAPOXClaudin18.2(G/GEJ)2023III(TranStar301)•20234MFDSIII(TranStar301)•20236(ASCO)osemitamab (TST001)CAPOX(G/GEJ)TranStar102C(PFS)9.5(DoR)9.9TranStar101TranStar101Ibosemitamab (TST001)osemitamab (TST001)mFOLFOX6(G/GEJ)•20236(ESMO GI)osemitamab (TST001)(CAPOX)Claudin18.2(G/GEJ)I/IITranStar102C9.5PFSosemitamab (TST001)Claudin18.2(G/GEJ)55%2023III(TranStar301) Osemitamab (TST001)CDx GMPClaudin18.2 CDxosemitamab (TST001) TST002 (Blosozumab) •20231TST00232 •20233TST002IIIND •20235TST002I(NCT05391776)(CSOBMR)2023TST0023285TST002853.52%5.94%1.30%2.24%(2.77%)blosozumabII •20236II TST003GREMLIN-1 •20231TST003IND•20233TST003 (NCT05731271)(FIH)(NCT05731271)•20234(AACR)2023TST003TST003(CRC)(CRPC) TST005PD-L1/TGF-β •20236(ASCO)ITST005SDPD-1PK/PDTGFβ-1PD-L1 TST010T •20234(AACR)2023TST010TST010TMEPD-1/PD-L1 Osemitamab (TST001ADCCClaudin18.2 •BMS82osemitamab (TST001)TranStar102•(CDx)Claudin18.2CDx•osemitamab (TST001)Claudin18.2 CMCCDMO •(ICB)•CDMO•(MCC)ComboGMP•ADCADC CMC •osemitamab (TST001)•osemitamab (TST001)Pre-PPQ) CDMO •2023CDMOCHOADCCMC•202212ADC osemitamab (TST001)osemitamab (TST001)Claudin18.2III(MFDS)Claudin18.2 IMTBCMCIND(BLA)IND(ICB)osemitamab (TST001)TST002CDMO 13 PD-L1=1VEGFR2=2TGFβ=βMASP2=2IND=FIC=HPV=BMP=TACI=CAMLCAML=NSCLC=SLE=TMA=IgA=ACombo=Chemo=VEGFRi=2 (1) (2) 2023 osemitamab (TST001)MSB0254TST003 TST005 TST006 TST010 TST012 TST013 •Osemitamab (TST001)Claudin18.2III(TranStar301)osemitamab (TST001)Claudin18.2(MFDS)2023FDAClaudin18.2 •MSB0254VEGFR2MSB0254IRP2D•TST003GREMLIN-1(FIH)•TST005PD-1/PD-L1TGF-βPD-1/PD-L1TST005I2023•TST006Claudin18.2-PD-L1•TST010TT•TST012ADCC•TST013ADC TST005MSB0254TST003 TST010osemitamab (TST001)osemitamab (TST001)Claudin18.2TST003MSB0254 OsemitamabTST001ADCCClaudin18.2 Osemitamab (TST001)Claudin18.2ADCCClaudin18.2(G/GEJ)Osemitamab(TST001)Claudin18.2 Osemitamab (TST001)II2023III(MFDS)III(TranStar301)osemitamab(TST001)Claudin18.22023FDA 2023osemitamab (TST001) •202312023(ASCO)(GI 2023)osemitamab (TST001)CAPOX(G/GEJ)I/II(TranStar102)•20233Claudin18.2PET[89Zr]Zr-DFO-TST001•20233FDAosemitamab (TST001)•20234ADCCClaudin18.2osemitamab (TST001)I/IITranstar102NCT04495296 CosemitamabCAPOXGosemitamabCAPOXClaudin18.2(G/GEJ)2023III(TranStar301)•20234MFDSIII(TranStar301)•20236(ASCO)osemitamab (TST001)CAPOX(G/GEJ)TranStar102C(PFS)9.5(DoR)9.9TranStar101TranStar101Ibosemitamab (TST001)osemitamab (TST001)mFOLFOX6(G/GEJ) •20236(ESMO GI)osemitamab (TST001)(CAPOX)Claudin18.2(G/GEJ)I/IITranStar102C9.5PFSosemitamab (TST001)Claudin18.2(G/GEJ)55%2023III(TranStar301) OSEMITAMAB (TST001)CDX GMPClaudin18.2 CDxosemitamab (TST001) TST003GREMLIN-1 TST003GREMLIN-1 •20231TST003IND•20233TST003(FIH)(NCT05731271)•20234(AACR)2023TST003TST003(CRC)(CRPC) TST005PD-L1/TGF-β TST005-β(TGF-β)-1 (PD-L1)TST005I2023 •20236(ASCO)ITST005SDPD-1PK/PDTGFβ-1PD-L1 MSB0254VEGFR2 MSB0254VEGFR2MSB0254VEGFR-2VEGFR-2VEGFR-2 •IRP2D•MSB0254TST001TST003TST005 MSB2311PD-L1 MSB2311PD-L1PD-(L)1pHPD-L1PD-L1MSB2311osemitamab (TST001)osemitamab (TST001)MSB23112022 TST010T TST010ADCCT(Tregs)Tregs •20234(AACR)2023TST010TST010TMEPD-1/PD-L1 TST006Claudin18.2-PD-L1 TST006Claudin18.2PD-L1Claudin18.2PD-1/PD-L1Claudin18.2 TST012ADCC TST012ADCC TST013ADC ADC TST002TST004TST008TST801 TST002TST004IgATST801(SLE)1844 TST002 (Blosozumab) TST00252BlosozumabII(BMD)2270mg12BlosozumabBMD17.7%BMD6.2% •20231TST00232 •20233TST002IIIND •20235TST002I(NCT05391776)(CSOBMR) 2023TST0023285TST002853.52%5.94%1.30%2.24%(2.77%)blosozumabII •20236II TST004MASP-2 TST0042 (MASP2)TST004IgAMASP2I TST008MASP-2BAFF TST008MASP2B TST801 TST801BSLE 18A.08(3) IND2023(FIH)ADCC(ADC)SLEINDB osemitamab (TST001)BMSTST002TST004 Osemitamab (TST001) osemitamab (TST001)
